specializes in biotechnology reagents, genomics, proteomics, and biopharmaceutical research companies. He was the founding CEO of Coda Genomics, a synthetic biology and biofuels company. Dr. Molinari is on the biotech screening committee of the Life Science Angels. He served as a genomics affiliate to the Institute for the Future, a Menlo Park-based think tank. He was the co-founding CEO and president of Protogene Laboratories, Inc., and from 1994 to 1996 led that company to become the world's largest supplier of custom DNA before it was acquired by Life Technologies, Inc. (now Invitrogen). He then ran a spin-off of Protogene for several years which developed ink jet technology for custom DNA chips. Prior to Protogene, Dr. Molinari served as a strategic advisor in the startup of Nanogen, Affymetrix, and Sequenom. Earlier, Dr. Molinari served as the founding CEO of Avitech Diagnostics, a company with DNA sequencing and mutation detection technology (which became part of Variagenics, Inc.) and was a consultant specializing in biotechnology at McKinsey & Co. Dr. Molinari has an A.B. and an MBA from Dartmouth College and a Ph.D. in biophysical chemistry from Brown University.
did postdoctoral research in the Department of Biochemistry, University of Oxford, UK, from 1995 to 2000, focusing on the overlap of bioorganic, combinatorial and surface chemistries. From 2000 to 2002 (San Diego, USA), and from 2002 to 2006 (UK) he worked in the biotech industry developing chemical tools for genomics and proteomics. At Retrotope, Dr. Shchepinov has focused on the use of stable isotopes as a fortification of essential nutrients to protect against diseases of aging and age-related oxidative stress. Dr. Shchepinov received his MS in chemistry and biotechnology from the Mendeleev Institute of Chemical Technology, Moscow, USSR, and a PhD in bioorganic chemistry from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, in 1994.
is chairman of Armetheon, a California company conducting a Phase 3 trial of its novel oral anticoagulant. From 2011 till 2015 as CEO of Heart Metabolics he raised capital for and organized the late stage development of an orphan treatment for a rare genetic heart disease, hypertrophic cardiomyopathy (HCM). In 2007 Peter cofounded Optivia Biotechnology a leading transporter biology company. In 1997 Peter co-founded ARYx Therapeutics (NASDAQ:ARYX) where as CEO then as president from 2005 to 2010 he co-invented and developed 4 novel drugs. In 1990 he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996 he in-licensed and invented several successful pharmaceuticals. CV Therapeutics was acquired by Gilead for $1.5B in cash in 2009. Prior to 1992, Peter was as an assistant professor of medicine at Washington University in St. Louis where his research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates the epithelial mesenchymal transition (EMT). He received his medical degree from University of Liverpool in 1980 and undertook post-graduate training at Johns Hopkins Hospital and The University of Virginia. Peter is a board certified cardiologist, a Fellow of the American College of Cardiology (FACC), co-inventor on 50 patents and author of 29 original scientific articles in Science, Biochemistry, Circulation, Cancer, JCI, and JBC. He serves as adjunct clinical faculty at Stanford University and as a board member of the California Healthcare Institute (CHI) where he was responsible for championing various pieces of legislation in particular, the 2011 Leahy-Smith Patent Reform Act and the 2012 GAIN (Generate Antibiotic Incentives Now) Act.
brings to Retrotope over 25 years of operational, financial and capital markets experience in life sciences, software and investment banking. As a partner of FLG Partners, Ms. Rubinstein’s consulting CFO roles have included ArmaGen, EpiBiome, iPierian (acquired by BMS), True North and Tunitas. Ms. Rubinstein has also served as CFO or run finance and administration at public and private companies including PaxVax, Ingenuity Systems (acquired by QIAGEN), Solexa (acquired by Illumina) and ChemoCentryx. Earlier, she served as an investment banker at Lehman Brothers, Scully Brothers & Foss and Merrill Lynch Capital Markets. Ms. Rubinstein holds BA and MA degrees in Economics from UCLA.
brings to Retrotope over 30 years of experience in developing pharmaceutical products. She has served in a number of senior leadership roles in product development, resulting in asset advancement from research through clinical trials and approvals. Roles included VP of Operations at Signature Therapeutics, Senior VP of Development at Durect Corporation, Head of Development, Vascular Therapeutics, Head of Program Management and Research Scientist at ALZA Corporation. As the founder and President of VSI Development consulting firm, Ms. Magruder has provided support to both large and small companies since 2004 in various aspects of product development, including portfolio analysis, program management, clinical, regulatory and technical development. Ms. Magruder is an inventor on over 50 patents, and holds an MBA from Santa Clara University and a B.S. in Animal Science from the University of California Davis.
has twenty years of experience managing global Phase I to Phase IV clinical studies focusing on various indications. Prior to joining Retrotope, Mr. Heerinckx served as Associate Director of Clinical Operations at Theravance for three years, where he lead the anti-infectious disease program overseeing a global Phase 3 study in treatment of bacteremia with an IV antibiotic drug. Prior, Mr. Heerinckx lead a clinical operations team at Anacor Pharmaceuticals overseeing studies in support of the development of three molecules. M. Heerinckx worked extensively on Phase 3 studies in the treatment of onychomycosis with a topical drug, and Phase 2 studies in the treatment of psoriasis and atopic dermatitis with a topical drug. Prior, Mr. Heerinckx worked at ARYx Therapeutics as Sr. Clinical Program Manager for three years where he managed a large global Phase 2 clinical study of anti-arrhythmic drug with 70 sites in four countries. Mr. Heerinckx also held various positions in clinical research at Scios, Inc. for nearly 10 years, where he managed and planned several studies from 1996 to 2005. Mr. Heerinckx also worked at Alza as part of the regulatory compliance team. He earned his Pharmacist Degree and Industrial Pharmacist Degree from the University of Leuven in Belgium.
has over twenty five years of experience providing Development and Project Management for various start-up and start-up/large-Pharma ventures. Her areas of expertise include project management, CMC management, regulatory, and clinical operations support. Prior to joining Retrotope, Ms. Schlesinger worked with over 15 companies in various consulting roles, and has served in various positions of project management leadership, process development and engineering for companies including Pearl Therapeutics/AstraZeneca, 3V Biosciences, Incline Therapeutics/The Medicines Co, Medicines360, Medimmune, Medivation/Astellas, Achaogen, Genitope, Nektar/Novartis, Cygnus and others. She holds a BS in Mechanical Engineering from The University of Pittsburgh.
Knobbe Martens Olson & Bear LLP
Wilson Sonsini Goodrich & Rosati